Adhera Therapeutics Inc (ATRX) financial statements (2021 and earlier)

Company profile

Business Address 4721 EMPEROR BOULEVARD
DURHAM, NC 27703
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 400121
Cash and cash equivalents 400121
Receivables 0   10
Inventory, net of allowances, customer advances and progress billings 0    
Inventory 0     
Prepaid expense 0  0  
Other current assets    0  
Other undisclosed current assets 000 00
Total current assets: 500131
Noncurrent Assets
Property, plant and equipment 0     
Intangible assets, net (including goodwill) 066777
Goodwill  44   
Intangible assets, net (excluding goodwill) 032777
Other noncurrent assets    0  
Total noncurrent assets: 066777
TOTAL ASSETS: 566898
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 222223
Accounts payable 011112
Accrued liabilities 111110
Employee-related liabilities    002
Taxes payable     0 
Interest and dividends payable 1     
Debt  00  2
Due to related parties 010   
Other undisclosed current liabilities  20 (0)1
Total current liabilities: 263226
Noncurrent Liabilities
Liabilities, other than long-term debt    222
Deferred tax liabilities, net   222
Other undisclosed noncurrent liabilities    396
Total noncurrent liabilities:    5129
Total liabilities: 26371415
Stockholders' equity
Stockholders' equity attributable to parent, including: 3030(4)(7)
Common stock 001   
Additional paid in capital 2985335333 
Accumulated deficit (26)(8)(2)(334)(338)(331)
Other undisclosed stockholders' equity attributable to parent 0  00324
Total stockholders' equity: 3030(4)(7)
TOTAL LIABILITIES AND EQUITY: 566898

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 0  112
Revenue, net  112
Cost of revenue
(Cost of Goods and Services Sold)
 (0)     
Gross profit: (0)  112
Operating expenses (15)(6)(1)(5)(4)(2)
Operating loss: (16)(6)(1)(4)(4)(0)
Nonoperating income (expense) (1)(0)(0)7(3)(1)
Interest and debt expense (1)(0)(0) 0(2)
Income (loss) from continuing operations before equity method investments, income taxes: (18)(6)(1)3(6)(4)
Other undisclosed income (loss) from continuing operations before income taxes 100 (0)2
Income (loss) from continuing operations before income taxes: (17)(6)(1)3(6)(2)
Income tax expense (benefit)  (0)(0)  0
Net income (loss) attributable to parent: (17)(6)(1)3(6)(2)
Preferred stock dividends and other adjustments (1)     
Other undisclosed net loss available to common stockholders, basic    (1)  
Net income (loss) available to common stockholders, diluted: (18)(6)(1)3(6)(2)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net income (loss): (17)(6)(1)3(6)(2)
Comprehensive income (loss), net of tax, attributable to parent: (17)(6)(1)3(6)(2)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: